inTEST (INTT) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for inTEST in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INTT shares.
View INTT analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1-year price objectives for inTEST's stock. Their INTT share price forecasts range from $20.00 to $26.00. On average, they anticipate the company's stock price to reach $22.67 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for INTT or view top-rated stocks among Wall Street analysts.

inTEST's stock was trading at $10.30 at the beginning of the year. Since then, INTT stock has increased by 119.8% and is now trading at $22.64.
View the best growth stocks for 2023 here.

inTEST saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 351,300 shares, an increase of 6.5% from the April 30th total of 329,900 shares. Based on an average daily volume of 194,800 shares, the short-interest ratio is presently 1.8 days. Currently, 3.4% of the company's stock are short sold.
View inTEST's Short Interest.

inTEST Co. (NYSEAMERICAN:INTT) posted its quarterly earnings data on Friday, May, 5th. The semiconductor company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.08. The semiconductor company had revenue of $31.92 million for the quarter, compared to analysts' expectations of $30.79 million. inTEST had a trailing twelve-month return on equity of 20.18% and a net margin of 8.58%.

inTEST updated its second quarter 2023 earnings guidance on Sunday, May, 7th. The company provided earnings per share guidance of $0.25-$0.30 for the period, compared to the consensus estimate of $0.29. The company issued revenue guidance of -.

Based on aggregate information from My MarketBeat watchlists, some companies that other inTEST investors own include Baozun (BZUN), Gilead Sciences (GILD), Applied Materials (AMAT), Main Street Capital (MAIN), Pfizer (PFE), Johnson & Johnson (JNJ), Nektar Therapeutics (NKTR), AbbVie (ABBV), International Business Machines (IBM) and Lam Research (LRCX).

inTEST trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INTT."

inTEST's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.05%), Dimensional Fund Advisors LP (4.99%), BlackRock Inc. (2.12%), Royce & Associates LP (1.42%), Royce & Associates LP (1.42%) and Acadian Asset Management LLC (1.38%). Insiders that own company stock include Gerald J Maginnis, Joseph W Iv Dews, Richard N Jr Grant and Scott Eric Nolen.
View institutional ownership trends.

Shares of INTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INTT stock can currently be purchased for approximately $22.64.

inTEST (NYSEAMERICAN:INTT) has a market capitalization of $251.98 million and generates $116.83 million in revenue each year. The semiconductor company earns $8.46 million in net income (profit) each year or $0.98 on an earnings per share basis.

The company employs 303 workers across the globe.

inTEST's mailing address is 804 E Gate Dr Ste 200, MOUNT LAUREL, NJ 08054-1209, United States. The official website for the company is www.intest.com. The semiconductor company can be reached via phone at (856) 505-8800, via email at laura@ga-ir.com, or via fax at 856-505-8801.